The findings highlight the therapeutic potential of GLP-1 RA to address a major unmet need for evidence-based treatments for reducing obesity among patients with ACHD, with and without heart failure. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.